In this video, health care analyst David Williamson takes a look back on the week so far for the Food and Drug Administration advisory committee. A trifecta of recommendations for approval greeted investors, although not all thumbs-ups are equal. Watch and find out what this means for investors of the three companies.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
3 FDA Approval Recommendations
This week was a trifecta of success for these biotechs.
David Williamson holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Stocks Mentioned


*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.